| Ibrutinib/R-CHOP Combination Achieves 100% Response Rate in Non-Hodgkin Lymphoma | ||
| Read more >> | ||
| Ganetespib-Docetaxel Combination Improves Survival in GALAXY-1 Trial | ||
| Read more >> | ||
| Proteins Identified as Potential Biomarkers for Response in KRAS-Mutated NSCLC go to targeted healthcare communications for more! targetedHC. |
Wednesday, July 31, 2013
CAN YOU BEAT 100% IN LYMPHOMA MANAGEMENT?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment